Exploring the Perception and Decision-Making Process of Palliative Care among Haematology Malignancy Patients and Their Family Caregivers: An Integrative Review
Exploring the Perception and Decision-Making Process of Palliative Care among Haematology Malignancy Patients and Their Family Caregivers: An Integrative Review
Poster 673 | Presenting author: Yong-Jhu Emily Sun
Belantamab mafodotin is now TGA-registered for people with multiple myeloma who have had at least one prior line of therapy. Available exclusively to CNSA members, we encourage you to login and listen today!
T-cell engagers, bispecifics and CAR-T are changing myeloma care fast. Two HSANZ events in Sydney and Adelaide will help you get up to speed, and the Adelaide seminar is free, with a virtual option.
Gain practical insights into understanding and responding to the evolving needs of people living with CML, from diagnosis through treatment and beyond.
As of 1 September 2026, nurse practitioners have been able to prescribe PBS-listed medicines for chronic myeloid leukaemia (CML) as a continuation of an existing therapy, where care is shared with a medical practitioner.
Discover the free support services available through Cancer Council Victoria and how they can enhance the care you provide to patients, families and carers.
What should you look for when a patient's family history raises questions about inherited cancer risk? And what should you do next? This month's Nursing Excellence in Cancer Care explores this increasingly important part of cancer care.
